
Krystal Biotech rated 'Buy' on strong Vyjuvek sales and promising drug pipeline
Krystal Biotech is rated a 'Buy' due to strong sales of Vyjuvek, a drug approved for dystrophic epidermolysis bullosa (DEB), which generated $119.2 million in Q2 revenue and is expanding globally. The company maintains a strong $1.1 billion cash posi...





